US : FDA says daily aspirin isn't for everyone
US : FDA says daily aspirin isn't for everyone

US : FDA says daily aspirin isn’t for everyone

The U.S. Food and Drug Administration (FDA) has denied a citizen’s petition from Bayer to add “primary” prevention of heart attacks and strokes to aspirin labeling.

Doctors say there is a clear benefit for those who have had a heart attack or a stent or bypass procedure. Aspirin inhibits one of the enzymes that causes blood clotting and can help prevent a recurrence. But for those who have never had a heart attack, they say a daily dose of aspirin may cause more harm than good.

“On the flip side, there’s a price to pay by being on aspirin. You’re more likely to develop some gastrointestinal problems including gastrointestinal bleeding, which may be almost as serious as some of the smaller heart attacks that we deal with,” Gogo explained. “So in balance, there is no overall benefit to being on aspirin in the overall population.”

That may be a tough pill to swallow for the millions who have long believed that an aspirin a day will keep a heart attack away. So until further studies can prove otherwise, the FDA says most people should focus on lowering their blood pressure and cholesterol, not a daily a dose of aspirin.

The FDA’s announcement this week was prompted by its recent decision to block the pharmaceutical company, Bayer, from labeling and marketing its product as a heart attack prevention drug for those who don’t have heart problems.


  • About News

    Web articles – via partners/network co-ordinators. This website and its contents are the exclusive property of ANGA Media Corporation . We appreciate your feedback and respond to every request. Please fill in the form or send us email to: [email protected]

    Check Also

    Brian Laundrie news: 'We're not wasting our time,' police commander says

    Brian Laundrie news: ‘We’re not wasting our time,’ police commander says

    VENICE, Fla. – Six days into the search for Brian Laundrie, police in North Port …

    Leave a Reply